As Of November 27, 2023, United Therapeutics Announced An Amendment Extending The Term Of Its Exclusive License Agreement With Eli Lilly Covering US Marketing, Promotion, And Sale Of Adcirca (Tadalafil) Tablets Through December 31, 2026 - 8K
Portfolio Pulse from Benzinga Newsdesk
United Therapeutics has extended its exclusive license agreement with Eli Lilly for the marketing, promotion, and sale of Adcirca (tadalafil) tablets in the US until December 31, 2026. The agreement, which was set to expire on December 31, 2023, allows United Therapeutics to continue commercializing Adcirca for pulmonary hypertension treatment. Other terms of the agreement remain unchanged.
November 29, 2023 | 11:14 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
United Therapeutics benefits from an extended term for its exclusive license to market Adcirca in the US, potentially ensuring stable revenue from the drug until the end of 2026.
The extension of the exclusive license agreement is likely to have a positive impact on United Therapeutics' stock in the short term as it secures a revenue stream from Adcirca for an additional three years beyond the original expiration date. This could be seen as a positive development by investors, as it provides more certainty regarding the company's future earnings from this product.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100
NEUTRAL IMPACT
Eli Lilly's extension of the license agreement with United Therapeutics for Adcirca allows it to continue benefiting from the partnership without direct involvement in the US marketing and sales.
For Eli Lilly, the impact of the extended agreement is likely to be neutral in the short term. While the company will continue to benefit from the licensing revenues, the extension was expected and does not significantly alter the existing arrangement. The impact on Eli Lilly's overall financial performance is likely to be moderate given the size of the company and its diverse portfolio.
CONFIDENCE 80
IMPORTANCE 50
RELEVANCE 50